Composite Interceptive Med Sciences laboratories Private limited (CIMED) is a R&D company working towards creating a novel genre of therapeutics. We are pioneers in Interceptive medicine, a new paradigm in health care which targets diseases along its continuum, even before the manifestation of a diagnosable disease. Our approach is not to replace current pharmaceutical standard of care, but to optimize clinical outcomes using our scientifically validated approach to management using Interceptive medicines. This is enabled by out complex computational approach, combining genomic sequencing data, related knowledge on pathophysiology of disease states, applying current rationale of pharmaceutical research and exploration of different systems of medicine. CIMED offers a new Polymolecular approach to looking at medical therapeutics for the future. Here, diseases are modelled and a composite approach to management is created.